HOME › DRUGS › IBRITUMOMAB TIUXETAN
ACTIVE SUBSTANCE / INN

IBRITUMOMAB TIUXETAN

Brand name(s): ZEVALIN, Zevalin
FDA LISTED
EMA LISTED
PRESCRIPTION
LAPSED
BLA125019
Lymphoma, Follicular
ACTIVE SUBSTANCE
Ibritumomab Tiuxetan
REGULATORS
FDA · EMA
SPONSORS / MAH
SPECTRUM PHARMS, Ceft Biopharma s.r.o.
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ZEVALINBLA125019SPECTRUM PHARMSPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ZevalinCeft Biopharma s.r.o.Lapsed16/01/2004Lymphoma, Follicular

FULL INTELLIGENCE ON IBRITUMOMAB TIUXETAN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →